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In-utero exposure to antihypertensive medication and
neonatal and child health outcomes: a
systematic review
Catherine A. Fittona, Markus F.C. Steinera, Lorna Aucotta, Jill P. Pellb, Daniel F. Mackayb
Michael Flemingb, and James S. McLaya
See editorial comment on page 2161
Background: Although medication is generally avoided
wherever possible during pregnancy, pharmacotherapy is
required for the treatment of pregnancy associated
hypertension, which remains a leading cause of maternal
and fetal morbidity and mortality. The long-term effects to
the child of in-utero exposure to antihypertensive agents
remains largely unknown.
Objective: The aim of this study was to systematically
review published studies on adverse outcomes to the child
associated with in-utero exposure to antihypertensive
medications.
Methods: OVID, Scopus, EBSCO Collections, the Cochrane
Library, and Web of Science databases were searched for
relevant publications published between January 1950 and
October 2016 and a total of 688 potentially eligible studies
were identified.
Results: Following review, 47 primary studies were eligible
for inclusion. The Critical Appraisal Skills Programme
checklist was used to assess study quality. Five studies
were of excellent quality; the remainder were either
mediocre or poor. Increased risk of low birth weight, low
size for gestational age, preterm birth, and congenital
defects following in-utero exposure to all antihypertensive
agents were identified. Two studies reported an increased
risk of attention deficit hyperactivity disorder following
exposure to labetalol, and an increased risk of sleep
disorders following exposure to methyldopa and clonidine.
Conclusion: The current systematic review demonstrates a
paucity of relevant published high-quality studies. A small
number of studies suggest possible increased risk of
adverse child health outcomes; however, most published
studies have methodological weaknesses and/or lacked
statistical power thus preventing any firm conclusions
being drawn.
Keywords: adverse drug event, antihypertensive agents,
child health, drug exposure in pregnancy, female,
hypertension, in-utero exposure, pharmacovigilance,
preeclampsia, pregnancy-induced hypertension
Abbreviations: ACEi, angiotensin-converting enzyme
inhibitor; ARB, AT1 blocker; CASP, Critical Appraisal Skills
Programme; CI, confidence interval; OR, odds ratios;
PRISMA, Preferred Reporting Items for Systematic Reviews
and Meta-Analyses; RCT, randomized controlled trials; RR,
relative risk
INTRODUCTION
H
ypertensive disorders of pregnancy have been
identified as the leading cause of maternal death
in industrialized countries, complicating approxi-
mately 7% of pregnancies [1,2].
Prior to pregnancy, approximately 3% of women have an
existing diagnosis of hypertension of whom a quarter will
go on to develop preeclampsia [2,3]. A further 4% will
develop hypertension during the course of their pregnancy
and also be at higher risk of developing preeclampsia [4].
Consequently, there has been a move to treat hyper-
tensive women of childbearing age more aggressively in an
attempt to normalize blood pressure (BP) prior to and
during pregnancy and reduce the occurrence of preeclamp-
sia [5]. Despite hypertensive disorders of pregnancy being a
common problem and suggestions that hypertension
during pregnancy may influence the developing fetus
and child, the efficacy of antihypertensive agents in terms
of maternal and fetal outcomes and the possible long-term
effects of in-utero antihypertensive exposure on the devel-
oping fetus and child remain largely unknown [6].
Although in-utero exposure to any medication during the
first trimester is associated with the highest risk of teratogenic
malformations, exposure during the second and third trimes-
ters has also been linked to functional and behavioural
abnormalities,whichmaynotbe immediatelyapparent [7–9].
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Review
Although the fetogenic and teratogenic risks associated
with angiotensin-converting enzyme inhibitors (ACEi) and
AT1 blockers (ARB) use during pregnancy are well recog-
nized [4] the potential effects of methyldopa, beta-blockers,
such as labetalol and the calcium channel blocker nifedi-
pine, are less clear [9,10]. In-utero exposure to these agents
has been associated with low birth weight, childhood
depression, delayed neurocognitive development [11,12],
increased incidence of childhood asthma [12,13], and neo-
natal seizures and hematological disorders [14,15]. How-
ever, the data from any one study are not sufficiently robust
to make meaningful comment on the strength of these
associations [13,16].
To determine whether in-utero exposure to antihyper-
tensive medication is associated with adverse child out-
comes, we reviewed primary literature reporting child
outcomes following exposure in utero to one or more
antihypertensive medications compared with unexposed
children.
METHODS
Search strategy
A systematic review protocol was designed as per standard
Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) guidelines [17]. The databases Medline,
Cumulative Index to Nursing and Allied Health Literature
(CINAHL), Cochrane Database of Systematic Review library,
Scopus (Elsevier), and EBSCO (psycINFO, CINAHL Plus)
were searched for publications from January 1950 toOctober
2016 inclusive (last search 10October 2016), using the search
terms (contained in keywords, title, or abstract) of prenatal,
antenatal, calcium channel blocker, beta blocker, ACEi,
adrenergic receptor antagonist/blocker, alpha-2 adrenergic
receptor agonist, angiotensin II receptor, antihypertensive,
hydralazine, sodium nitroprusside, clonidine hydrochloride,
moxonidine, renin inhibitor, thiazide, loop diuretic, and
potassium sparing diuretic. Ineligible articles were excluded
using the following search terms (contained in keywords,
title, or abstract) animal, rat, mice, haemanginoma, mouse,
Doppler, ultrasound, ambulatory, willingness to pay, adher-
ence, transplant, herbal, tumor, imaging, HIV, mercury,
vitamin, and gene. Wildcard symbols, truncation, combi-
nations of search terms using Boolean operators, and alter-
ative spellings were used. Included studies reported
pregnant female patients of any ethnicity; exposed to one
or more agents of interest (beta-adrenoceptor blocking
drugs; vasodilator antihypertensive drugs; centrally acting
antihypertensive drugs; alpha-adrenoceptor blocking drugs;
ACEi; angiotensin II receptor antagonists; renin inhibitors;
calcium channel blockers; thiazide diuretics; loop diuretics;
potassium sparing diuretics) administered via any route
compared with no drug, placebo or any active antihyper-
tensive comparator. There was no restriction on the type of
hypertensionbeing treated, that is, preexistinghypertension,
gestational hypertension, and preeclampsia. Eligible studies
evaluated any health outcomes in offspring, as measured
using well defined diagnostic criteria and doctor diagnoses.
Studies reporting the results of controlled trials, case–control
studies, cohort studies, and meta-analysis with synthesized
data were included.
The reference lists from eligible papers were scanned for
other relevant studies. The search was limited to English
and German language articles. Narrative and systematic
reviews (with no synthesis of data), studies published only
as abstracts, letters, or conference proceedings, discussion
papers, animal studies, and editorials were excluded.
Initial screening of titles was carried out to identify
potentially relevant studies, followed by screening of
abstracts and then by full paper review. All titles and
abstracts were independently evaluated by two reviewers
(M.S. and J.S.M.) for consistency of inclusion/exclusion.
Study review and data extraction
Quality assessments were conducted by two independent
reviewers (C.F. and M.S.) using a modified version of the
Critical Appraisal Skills Programme quality assessment tool
for randomized controlled trials [18], case–control studies
[19], and cohort studies [20]. Data extracted for randomized
controlled trials were: the generation of allocation
sequence, concealment of allocation, outcome measures,
and other risks of bias, and for case–control and cohort
studies, appropriateness of case and control recruitment,
inclusion and exclusion criteria clearly stated, appropriate
validation of cases, appropriate analyses, and sufficient
follow-up information. Where information was missing
from the studies, contact with authors was attempted,
where practical, via e-mail; however, no responses were
received. Due to lack of study homogeneity, meta-analysis
was not appropriate. Therefore, a narrative synthesis of the
results was conducted.
Registration and reporting
The current review was registered with the International
Prospective Register of Systematic Reviews: http://
www.crd.york.ac.uk/prospero/ [21]. The PRISMA checklist
was used to guide the reporting of the systematic review:
http://www.prisma-statement.org/.
RESULTS
The database searches retrieved 816 citations. Removal of
duplicates followed by review of titles and abstracts yielded
47 relevant studies. The PRISMA flowchart (Supplemental
file: Fig. 1, http://links.lww.com/HJH/A805) illustrates the
number of titles, abstracts, and full papers excluded.
In total, 22 studies were conducted in Europe; 16 in
North America, three in Asia, one in central America, and
one in Africa. Four of the 47 studies were multinational,
three of which were across continents [22–25]. Of these
47 studies, 29 were published after 2000. The reported
study populations ranged from 22 to 2529 636 participants
(Tables 1–4). Seven studies reported on all classes of
antihypertensive medication [26–32], five reported on
calcium channel blockers only [23,33–36], 12 on beta-
blockers only [37–48], two on methyldopa only [49,50],
six on methyldopa and/or beta-blockers [11,13,51–54], two
on calcium channel blockers and/or beta blockers [12,55],
nine on ARBs or ACEis [22,28,29,56–60], one on clonidine
only [61], one diuretics only [25], one compared nifedipine
with prazosin [62], one compared nifedipine with hydrala-
zine [63], and one compared labetalol with hydralazine [64].
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Reported outcomes were predominantly the rate of mal-
formations and birth outcomes (i.e., perinatal death, birth-
weight, size for gestational age, and preterm birth), but four
publications also included childhood assessments at later
follow-up such as intelligence quotient (IQ) and behav-
ioural outcomes [11,13,49,61]. Results were reported as a
mixture of crude odds ratios (ORs), adjusted ORs (adjusted
OR) or relative risks (RRs).
Descriptive tables (Tables 1–6) showing drugs and out-
comes investigated were produced. Results where out-
comes were found to be significant in some way are
marked with Y, and those not found to be significant
marked with N.
Studies were categorized according to study design and
quality and bias assessed accordingly (Supplemental files:
Tables 7–9, http://links.lww.com/HJH/A805). No study
achieved the maximum score for quality, five were graded
as excellent [29,31,33,51] and 26 as fair [11–13,25–28,
30,32,35,40,42–45,47,49,50,52–54,60,62–64]. The remain-
der [16] were graded as poor quality primarily due to a lack
of appropriate controls, and/or documented methods for
selection of patients and controls for inclusion [22–24,
36–39,41,46,48,55,56,58,59,61,65].
For clarity and ease of interpretation, the results of the
eligible studies have been reported, according to the drug
of exposure, as early (birth to 1 month) and long-term (>1
month) outcomes.
Studies assessing early outcomes following any
antihypertensive exposure
Five case–control studies [26–28,30,31] and two cohort
studies [29,32] reported the effects of in-utero exposure,
on the fetus and child, of any antihypertensive agent. Table
1 reports study type, outcomes, and number of participants
for studies assessing in-utero exposure to any antihyper-
tensive medication. Two studies were graded as excellent
[29,31] and the other five studies [26–28,30,32] as mediocre
in quality.
In the cohort study of 1418 women, rated as excellent,
Lennestål et al. [29] reported that offspring exposed
to antihypertensive medication during pregnancy were
more likely to be born preterm [adjusted OR 3.3; 95%
confidence interval (CI) 2.9–3.8], small for gestational
age (adjusted OR 4.2; 95% CI 3.6–5.0) and be hypoglyce-
mic (adjusted OR 2.6; 95% CI 2.0–3.4) compared with
offspring not exposed to antihypertensive therapy during
pregnancy. Lennestål et al. [29] also reported an increased
odds of any congenital malformation (adjusted OR 1.5;
95% CI 1.2–1.9); particularly cardiovascular defects
(adjusted OR 2.6; 95% CI 1.9–3.5) and increased risk of
septal defects (RR 2.7; 95% CI 1.7–4.0). There was an
increased risk of congenital malformation with exposure
to two or more different groups of antihypertensive
patients (RR 4.0; 95% CI 1.8–7.6), compared with unex-
posed women. However, no increased risk of hypospadias
(RR 1.3; 95% CI 0.5–2.9) and central nervous system
malformations (RR 2.2; 95% CI 0.7–5.1) was reported in
offspring following in-utero exposure to any antihyper-
tensive agent.
In the case–control study rated as excellent, studying
major congenital anomalies (4155 cases, 54 878 controls),
and being small for gestational age (7445 cases, 48 889
controls), Nakhai-Pour et al. [31] reported increased odds
of being small for gestational age when mothers were
exposed to antihypertensive medication during the second
or third trimester of pregnancy, compared with no anti-
hypertensive exposure (adjusted OR 1.5; 95% CI 1.2–2.0).
There was no increased odds of major congenital anomalies
following exposure to antihypertensive medication during
pregnancy in any trimester, compared with no antihyper-
tensive exposure.
Banhidy et al. [26] reported the immediate outcomes of
pregnancy and efficacy of in-utero exposure to antihyper-
tensive medication among 37 734 offspring, in a case–
control study rated as mediocre. Both chronic and gesta-
tional hypertensions were assessed. Antihypertensive
TABLE 1. Characteristics of studies Included in the systematic review that assess any antihypertensive exposure
Lead Author
Year Reference
Arias
1979 [32]
Banhidy
2010 [26]
Caton
2008 [27]
Caton
2009 [28]
Lennestal
2009 [29]
Nakhai-Pour
2010a [31]
Nakhai-Pour
2010b [31]
Van Gelder
2015 [30]
Country US Hungary US US Sweden Canada Canada Netherlands
Study size 59 37 734 2887 9817 1063 238 56 334 59 033 12 821
Study design CS CC CC CC CS CC CC CC
Hypertension type CH CH/GH NK NK NK NK NK CH/GH/P
CASP Score (%) 67 53 76 76 87 94 94 82
Outcomes
Preterm birth Y Y
Small for gestational age N Y Y
Low birth weight N Y
Head circumference
Ponderal index
Perinatal mortality
Congenital defects Y Y Y Y Y Y
Seizures Y
Hypoglycaemia Y
IQ
Sleep disorders
Other long-term outcomes
Fetal behavioral states
Y denotes significant result reported for outcomes. N denotes no significant result reported for outcomes. CC, case–control study ;CH, chronic hypertension; CS, cohort study; GH,
gestational hypertension; NK, not known; P, preeclampsia; RCT, randomized controlled trial.
In-utero exposure to antihypertensive patients
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TABLE 2. Characteristics of studies Included in the systematic review that assess beta blocker exposure
Lead Author
Year Reference
Bayliss
2002 [37]
Caton
2009 [28]
Chan 2010
[11]
Cooper
2006 [60]
Davis
2011 [12]
Fidler
1983 [52]
Gazzolo
1998 [55]
Heida
2012 [38]
Country UK US Canada US US UK Italy Netherlands
Study size 491 9817 99 29 507 87 407 100 117 95
Study design CS CC CS CS CS RCT CS CS
Hypertension type CH NK NK NK NK NK GH P
CASP Score (%) 53 76 76 73 73 63 40 53
Outcomes
Preterm birth N
Small for gestational age Y N
Low birth weight Y N N
Head circumference N
Ponderal index Y Y
Perinatal mortality Y
Congenital defects Y Y
Seizures Y
Hypoglycaemia Y
IQ N
Sleep disorders
Other Long-term outcomes
Fetal behavioral states Y
Lead Author
Year Reference
Lennestal
2009 [29]
Lieberman
1978 [46]
Lip
1997 [39]
Lydakis
1999 [45]
Macpherson
1986 [48]
Meidahl
2012 [40]
Munshi
1992 [41]
Orbach
2013 [51]
Country Sweden UK UK UK UK Denmark India Israel
Study size 1063 238 23 398 312 22 911 685 129 100 029
Study design CS CS CS CS CS CS CS CS
Hypertension type NK NK NK NK NK NK GH NK
CASP Score 87 47 47 73 60 73 33 87
Outcomes
Preterm birth Y Y Y Y
Small for gestational age Y Y Y Y
Low birth weight Y Y Y Y
Head circumference N Y
Ponderal index Y Y
Perinatal mortality Y N
Congenital defects Y N
Seizures Y
Hypoglycaemia Y Y
IQ
Sleep disorders
Other long-term outcomes
Other immediate outcomes N
Lead Author
Year Reference
Pickles
1992 [42]
Plouin
1988 [53]
Ray
2001 [43]
Rubin
1983 [44]
Sibai
1987 [47]
Sibai
1990 [54]
Vigil-DeGracia
2006 [64]
Xie
2014 [65]
Country UK France Canada UK USA USA Panama Canada
Study size 144 176 1948 120 200 263 200 1223
Study design RCT RCT CS RCT RCT RCT RCT CS
Hypertension type GH NK CH GH P CH NK CH/GH
CASP Score (%) 63 88 60 75 75 81 81 47
Outcomes
Preterm birth Y N N
Small for gestational age N Y Y N
Low birth weight N N N
Head circumference N
Ponderal index
Perinatal mortality N N N
Congenital defects
Seizures Y
Hypoglycaemia N N N N
IQ Y
Sleep disorders
Other long-term outcomes
Fetal behavioral states
Y denotes significant result reported for outcomes. N denotes no significant result reported for outcomes. CC, case–control study; CH, chronic hypertension; CS, cohort study; GH,
gestational hypertension; NK, not known for the treated group, however the untreated hypertensive group had CH; NK, not known; P, preeclampsia; RCT, randomized controlled trial.
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treatment of mothers with chronic hypertension was associ-
ated with an increased risk of preterm birth (adjusted OR
1.5; 95% CI 1.3–1.8) compared with the untreated hyper-
tensive group. No significant increase was observed for
mothers treated for gestational hypertension (adjusted OR
1.2; 95% CI 0.9–1.5), compared with the untreated hyper-
tensive reference group. The authors also reported that
mothers with chronic hypertension, who were treated with
antihypertensive medication, had significantly lighter
babies (P< 0.0001) and increased odds of low birth weight
(adjusted OR 2.3; 95% CI 1.8–2.7) [26]. However, there was
no significant difference in low birth weight offspring
between mothers treated for gestational hypertension
(adjusted OR 1.5; 95% CI 1.0–2.1) and the untreated hyper-
tensive group [26].
Caton et al. [27] reported the exposure to in-utero anti-
hypertensive medication in a mediocre case–control study
of 758 offspring with hypospadias vs. 2058 offspring with-
out hypospadias. Early antihypertensive use (1 month
preconception to 4 months postconception) was not associ-
ated with increased odds of hypospadias (adjusted OR 1.4;
95% CI 0.7–2.9), although, late use of antihypertensive
TABLE 3. Characteristics for studies included in the systematic review that assess calcium channel blocker exposure
Lead Author
Year Reference
Bateman
2015 [33]
Davis
2011 [12]
Fenakel
1991 [63]
Gruppo
1998 [34]
Hall
2000 [62]
Magee
1996 [23]
Sorensen
2001 [35]
Weber-Schoendorfer
2008 [24]
Country US US Israel Italy S. Africa Canada; US; UK Hungary Germany; France; the Netherlands; Israel;
Spain; Italy; Finland
Study size 2529 636 87 407 49 283 150 156 54 016 1105
Study design CS CS RCT RCT RCT CS CC CS
Hypertension type NK NK P NK NK NK NK NK
CASP Score (%) 87 73 63 63 75 40 76 47
Outcomes
Preterm birth Y Y
Small for gestational age N
Low birth weight N N Y
Head circumference
Ponderal index
Perinatal mortality N N Y Y
Congenital defects Y N N Y N
Seizures N Y
Hypoglycaemia Y
IQ
Sleep disorders
Other long-term outcomes
Fetal behavioral states
Y denotes significant result reported for outcomes. N denotes no significant result reported for outcomes. CC, case–control study; CH, chronic hypertension; CS, cohort study; GH,
gestational hypertension; NK, not known; P, preeclampsia; RCT, randomized controlled trial.
TABLE 4. Characteristics for studies Included in the systematic review that assess angiotensin-converting enzyme inhibitor and
angiotensin receptor blocker exposure
Lead Author
Year Reference
Caton
2009 [28]
Cooper
2006 [60]
Diav-Citrin
2011 [22]
Karthikeyan
2011 [56]
Lennestal
2009 [29]
Li
2011 [57]
Moretti
2011 [58]
Tabacova
2003 [59]
Country US US Israel/Italy UK Sweden US Canada US
Study size 9817 29 507 1003 94 1063 238 465 754 388 108
Study design CC CS CS CS CS CS CS CS
Hypertension type NK NK NK NK NK NK NK NK
CASP Score (%) 76 73 47 33 87 93 53 33
Outcomes
Preterm birth Y Y Y Y
Small for gestational age Y Y
Low birth weight Y
Head circumference
Ponderal index Y
Perinatal mortality Y N Y Y
Congenital defects Y N N Y Y N Y
Seizures Y
Hypoglycaemia Y
IQ
Sleep disorders
Other long-term outcomes
Fetal behavioral states
Y denotes significant result reported for outcomes. N denotes no significant result reported for outcomes. CC, case–control study; CH, chronic hypertension; CS, cohort study; GH,
gestational hypertension; NK, not known; P, preeclampsia; RCT, randomized controlled trial.
In-utero exposure to antihypertensive patients
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medication (4 months postconception onwards) was
(adjusted OR 5.0; 95% CI 1.9–12.9). However, untreated
hypertension during pregnancy was also associated with
increased odds of hypospadias (adjusted OR 2.1; 95% CI
1.6–2.9).
In a second case–control study rated as mediocre, by
Caton et al. [28], 5021 cases with a cardiovascular malfor-
mation and 4796 controls were assessed and the prevalence
of hypertension and antihypertensive use during preg-
nancy was reported. Exposure to antihypertensive medi-
cation during the first trimester was associated with
increased odds of pulmonary valve stenosis (OR 2.6; 95%
CI 1.3–5.4), Ebstein malformation (OR 11.4; 95% CI 2.8–
34.1), coarctation of the aorta (OR 3.0; 95% CI 1.3–6.6), and
secundum atrial septal defects (OR 2.4; 95% CI 1.3–4.4).
Antihypertensive treatment initiated after the first trimester
was also associated with increased odds of pulmonary
valve stenosis (OR 2.4; 95% CI 1.1–5.4), perimembranous
ventricular septal defects (OR 2.3; 95% CI 1.2–4.6), and
secundum atrial septal defects (OR 2.4; 95% CI 1.3–4.4).
There were no increased odds associated with untreated
hypertension for any of the cardiovascular malformations
investigated.
Van Gelder et al. [30] reported increased odds of hypo-
spadias associated with treatment of chronic hypertension
in the early stages of pregnancy (adjusted OR 2.9; 95% CI
1.1–7.4) in a case–control study, rated as mediocre, assess-
ing a total of 5568 cases and 7253 controls. For mothers with
gestational hypertension, late initiation of antihypertensive
treatment was associated with increased odds of ventricular
septal defects (adjusted OR 2.7; 95% CI 1.1–6.8), and left-
sided cardiac defects (adjusted OR 4.3; 95% CI 1.5–12.3) in
offspring. Preeclampsia superimposed upon chronic hy-
pertension, with early use of antihypertensive medication,
was associated with increased odds of ventricular septal
defects (adjusted OR 3.7, 95% CI 1.3–10.7), left-sided
cardiac defects (adjusted OR 3.8; 95% CI 1.1–13.2), and
cleft lip/palate (adjusted OR 5.0; 95% CI 1.3–19.0) in off-
spring. However, untreated preeclampsia superimposed
upon chronic hypertension was also associated with car-
diovascular malformations (adjusted OR 3.7; 95% CI 1.4–
9.7), ventricular (adjusted OR 3.9; 95% CI 1.3–11.7), and
atrial septal defects (adjusted OR 6.5; 95% CI 1.8–23.7)
when compared with the untreated normotensive control
group. Untreated preeclampsia was also associated with
ventricular septal defects (adjusted OR 1.5; 95% CI 1.1–2.2),
and hypospadias (adjusted OR 2.4; 95% CI 1.4–4.0) com-
pared with the control group. There were no increased
odds of congenital malformations associated with untreated
gestational hypertension in comparison with the control
group. In a mediocre cohort study of 59 mildly hypertensive
women, Arias et al. [32] reported no significant differences
in gestational age, fetal weight, proportion of low birth
weight babies, Apgar scores at 1 and 5min, or intrauterine
growth restriction, between hypertensive women treated
with antihypertensive patients, and untreated hypertensive
women.
Any hypertensive summary. In summary, although seven
studies reported increased odds of preterm birth and low
birth weight in treated mothers, particularly those with
chronic hypertension and four studies, a possible increase
in the incidence of congenital malformations study designs
did not allow assessment of the relative importance of
hypertension vs. exposure to antihypertensive patients.
The ORs for perinatal mortality, preterm birth, and con-
genital cardiovascular defects are reported as Forest plots
in Supplementary Figs. 2–4, http://links.lww.com/HJH/
A805.
Beta-blocker exposure
One case–control study [28], 16 cohort studies [11,12,29, 37–
41,43,45,46,48,51,55,60,65], and seven randomized con-
trolled trials (RCTs) [42,44,47,52–54,64] have reported the
TABLE 5. Characteristics for studies Included in the Systematic Review that assess methyldopa exposure
Lead Author
Year Reference
Cockburn
1982 [49]
Fidler
1983 [52]
Orbach
2013 [51]
Weitz
1987 [50]
Xie
2014 [65]
Country UK UK Israel USA Canada
Study size 195 100 100 029 25 1223
Study design RCT RCT CS RCT CS
Hypertension type NK NK NK CH CH/GH
CASP Score (%) 69 63 87 75 47
Outcomes
Preterm birth Y N
Small for gestational age Y
Low birth weight N Y N
Head circumference Y N Y N
Ponderal index Y
Perinatal mortality N N
Congenital defects N
Seizures Y
Hypoglycaemia
IQ N Y
Sleep disorders
Other long-term outcomes N
Fetal behavioral states
Y denotes significant result reported for outcomes. N denotes no significant result reported for outcomes. CC, case–control study; CH, chronic hypertension; CS, cohort study; GH,
gestational hypertension; NK, Not known for the treated group, however the untreated hypertensive group had CH; NK, not known; P, preeclampsia; RCT, randomized controlled trial.
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effects of in-utero exposure tobeta-blockers, on the fetus and
child. Table 2 reports details on study type, outcomes, and
number of participants for studies assessing in-utero
exposure to beta-blocker medication. Eight studies were
poor [37–39,41,46,48,55,65], and14wereofmediocrequality
[11,12,28,40,42–45,47,52–54,60,64] with two studies being
of excellent quality [29,51].
In a cohort study of 1063 238 pregnant women, rated as
excellent, Lennestål et al. [29] reported increased odds of
cardiovascular malformations (adjusted OR 2.8; 95% CI
1.8–4.1) in beta-blocker-treated women, compared with
those who did not report antihypertensive use during
pregnancy. The authors [29] also reported 19 deaths among
the 1444 offspring exposed to any antihypertensive medi-
cation (RR 1.9; 95% CI 1.0–3.0); 15 of whom had been
exposed to a beta-blocker in either early or late pregnancy.
In a cohort study of 100 029 women, also rated as
excellent, Orbach et al. [51] reported increased odds of
preterm birth among the 107 women taking atenolol
(adjusted OR 2.7; 95% CI 1.6–4.6), in comparison with a
normotensive untreated reference group. The authors [51]
also reported increased odds of being small for gestational
age (adjusted OR 4.8; 95% CI 2.1–11.1), low birth weight
(adjusted OR 3.9; 95% CI 2.4–6.3), and intrauterine growth
restriction (adjusted OR 5.2; 95% CI 2.6–10.4) in offspring
exposed in-utero to atenolol during the third trimester,
compared with the normotensive untreated reference
group.
However, there was also increased odds of preterm birth
(adjusted OR 1.9; 95% CI 1.6–2.3), being small for gesta-
tional age (adjusted OR 2.1; 95% CI 1.4–3.0), and intra-
uterine growth restriction (adjusted OR 2.1; 95% CI 1.5–
2.9), for offspring exposed to untreated maternal hyperten-
sion in-utero compared with the normotensive untreated
reference group. The authors [51] did not report any sig-
nificant association with congenital defects (adjusted OR
1.3; 95% CI, 0.8–2.0) and no perinatal deaths occurred.
In a mediocre cohort of 911 685 women, Meidahl
Petersen et al. [40], reported increased odds of preterm
birth in the 2259 women taking any beta-blocker (OR
2.3; 95% CI 2.0–2.5) compared with untreated normo-
tensive women. The authors [40] also reported increased
odds of being small for gestational age (adjusted OR
2.0; 95% CI 1.7–2.4) and perinatal mortality (adjusted
OR 1.9; 95% CI 1.3–2.9) following exposure to beta-
blockers in offspring, compared with an untreated refer-
ence group.
Ray et al. [43], in a study of 1948 women rated as
mediocre, reported increased odds of preterm birth
(adjusted OR 5.1, 95% CI 3.8–6.9) and being small for
gestational age (adjusted OR 2.3; 95% CI 1.6–3.3) but no
significantly increase of perinatal mortality (adjusted OR
1.5; 95% CI 0.6–3.4) following in-utero exposure to beta-
blocker, in comparison with an untreated hypertensive
comparison group.
In a mediocre cohort study of 312 women, Lydakis et al.
[45] reported an increased risk of preterm birth (33.0 vs.
15.4%; P< 0.001), low birth weight (2.4 vs. 3.1 kg; P< 0.05),
and being small for gestational age (48.7 vs. 20.9%;
P< 0.001) following atenolol exposure compared with
an untreated hypertensive comparison group, with the
largest risk of being small for gestational age following
exposure to atenolol during early pregnancy (70, 30, and
39% for treatment started less than 20, 20–30, and more
than 30-week gestation, respectively; P¼ 0.01).
In a cohort study of 1223 women rated as poor, Xie et al.
[65] reported increased odds of infant hospitalization for
respiratory distress syndrome, sepsis, and seizures in those
who were exposed to labetalol during pregnancy, com-
pared with those who were exposed to methyldopa
(adjusted OR 1.5; 95% CI 1.0–2.2). The authors, however,
did not report increased odds of being born preterm
(adjusted OR 1.0, 95% CI 0.9–1.2), or perinatal mortality
(adjusted OR 1.0; 95% CI 0.3–3.0).
TABLE 6. Characteristics for studies included in the systematic review that assess long-term outcomes following in-utero exposure to
antihypertensive medication
Lead Author
Year Reference
Chan
2010 [11]
Cockburn
1982 [49]
Huisjes
1986 [61]
Pasker-De Jong
2010 [13]
Country Canada UK Netherlands Netherlands
Study size 99 195 44 202
Study design CS RCT CS CS
Hypertension type NK NK NK GH
CASP Score (%) 67 69 47 67
Outcomes
Preterm birth
Small for gestational age
Low birth weight
Head circumference Y N
Ponderal index
Perinatal mortality
Congenital defects
Seizures
Hypoglycaemia
IQ N N
Sleep disorders Y Y
Other long-term outcomes N N Y
Fetal behavioral states
Y denotes significant result reported for outcomes. N denotes no significant result reported for outcomes. CC, case–control study; CH, chronic hypertension; CS, cohort study; GH,
gestational hypertension; NK, not known; P, preeclampsia; RCT, randomized controlled trial.
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In a cohort study rated as poor, investigating the possible
effects of labetalol for the treatment of severe preeclampsia,
Heida et al. [38] reported no increased risk of low birth
weight (1.5 vs. 1.6 kg; P¼ 0.25), being small for gestational
age (21.8 vs. 22.2%; P¼ 0.96), or being born preterm (89.1
vs. 79.6%; P¼ 0.17), in 109 offspring, 55 of whom were
exposed in utero to labetalol [38]. The authors did however
report an increased risk of perinatal mortality (4.6 vs. 0%;
P¼ 0.02) associated with labetalol. In a poor cohort study of
491 women, Bayliss et al. [37] reported an increased risk of
being small for gestational age (70 vs. 21 or 26%), lower
birth weight (mean 2.2 vs. 3.1 kg; P< 0.01), and lower
ponderal index (22.3 vs. 22.6 or 24.5 kg/m3 104;
P< 0.01) following in-utero exposure to atenolol in the
first trimester of pregnancy, compared with untreated
hypertensive women.
Lip et al. [39] reported significantly lower mean birth
weight in offspring exposed to atenolol compared with
babies exposed to other beta-blockers or methyldopa, or
born to mothers with untreated hypertension (mean 2.2,
2.3, 2.7, and 2.8 kg, respectively; P< 0.001) in a cohort
study, rated as poor, of 398 women. The authors [39] also
reported a lower ponderal index, following in-utero
exposure to atenolol, in comparison with the untreated
hypertensive group (2.2 vs. 2.4 kg/m3 104; P¼ 0.001).
Caton et al. [28], in a mediocre case–control study of
9817 offspring, reported increased odds of cardiovascular
malformations (adjusted OR 2.6; 95% CI 1.9–3.5) and
pulmonary valve stenosis (adjusted OR 5.0; 95% CI 1.8–
13.8), following in-utero beta-blocker exposure, com-
pared with normotensive controls. In a mediocre cohort
study of 87 407 offspring, Davis et al. [12] reported that
exposure to beta-blockers during the third trimester
was associated with an increased risk of hypoglycemia
(RR 3.1; 95% CI 2.2–4.2), and feeding problems (RR 1.8;
95% CI 1.3–2.5), in comparison with the normotensive
untreated reference group; however, the authors did
not report any increased odds of any congenital defect
(OR 1.0; 95% CI 0.8–1.2) or cardiac defects (OR 1.9; 95% CI
0.7–5.2)
In a mediocre RCT of 100 women assessing fetal head
circumference and placental weight, Fidler et al. [52]
observed no significant differences between the effects
of in-utero exposure to oxoprenolol and those exposed
to methyldopa or the untreated control group. Rubin et al.
[44] reported the results of a mediocre RCT investigating the
in-utero effects of atenolol vs. placebo in 120 women with
mild-to-moderate pregnancy associated hypertension. The
authors reported no difference in intrauterine growth retar-
dation, Apgar score, incidence of hypoglycemia or hyper-
bilirubinemia, or neonatal BP between the two treatment
groups. However, they did report increased occurrence of
neonatal bradycardia in the atenolol exposed group
(P< 0.01). In a poor cohort study investigating the effects
of labetalol on 129 offspring, Munshi et al. [41] reported a
significantly increased incidence of hypoglycemia in off-
spring exposed to labetalol, compared with the reference
group who were exposed to other antihypertensive agents
(P< 0.01); however, there was no significant difference in
the incidence of intrauterine growth retardation or birth
asphyxia.
In a poor cohort study of 22 women, Macpherson et al.
[48] reported pregnancy outcomes of labetalol exposure
during pregnancy in hypertensive women (N¼ 11), com-
pared with a comparison group of unexposed, normoten-
sive women (N¼ 11). There was no difference in heart rate
(HR), respiratory rate or palmar sweating between the two
treatment groups; however, mean SBP in infants was sig-
nificantly different at 2-h post birth (P< 0.05). This differ-
ence disappeared after 72 h.
In an RCT of 176 women rated as mediocre, Plouin et al.
[53] reported no difference in HR, BP, respiratory rate or
glucose levels between labetalol and methyldopa exposed
offspring. In a mediocre RCT of 200 women with mild
preeclampsia, Sibai et al. [47] reported no significant differ-
ence in birth weight and neonatal ICU (NICU) admission
between a group treated with labetalol and hospitalization
and a group treated with hospitalization only. There was a
significant difference in offspring being small for gestational
age (19.1% with labetalol and hospitalization vs. 9.3% with
hospitalization only; P< 0.05).
Lieberman et al. [46] reported the results of a cohort
study, rated as poor, which involved eight hypertensive
women who took propranolol with or without other anti-
hypertensive patients, and a comparison group of 15 hyper-
tensive women who took antihypertensive patients, but did
not take propranolol. A significantly higher proportion of
offspring in the propranolol exposed group were below the
5th percentile for birthweight compared with the compari-
son group (propranolol 7/9 vs. other antihypertensive
patients 4/15; P¼ 0.02).
In a mediocre RCT of 263 women with mild-to-moderate
chronic hypertension, Sibai et al. [54] reported no signifi-
cant differences in preterm delivery, being small for gesta-
tional age, 1 and 5 min Apgar scores, gestational age,
birthweight, congenital abnormalities, fetal hypotension,
fetal bradycardia, and head circumference between the
control group and both the labetalol-treated and methyl-
dopa-treated groups. In a RCT of 200 women (100 given
labetalol, 100 given hydralazine) rated as mediocre, Vigil-
De Gracia et al. [64] reported a significant difference in
offspring with neonatal bradycardia (10.6% labetalol vs.
1.9% hydralazine; P¼ 0.008) and hypotension (10.6% labe-
talol vs. 3.9% hydralazine; P¼ 0.05). No differences in
birthweight, intrauterine growth restriction, hypoglycemia,
respiratory distress syndrome, 1 and 5min Apgar scores,
or NICU admissions were reported between the two
treatment groups.
In a poor cohort study to investigate functional develop-
ment of the fetal central nervous system, involving 117
women, 21 of whom were treated with nifedipine or
labetalol for pregnancy-induced hypertension, Gazzolo
et al. [55] reported disturbances in the development of
in-utero fetal behavioral recordings in the treated cohort.
However, when the authors matched exposed and unex-
posed cases for age and birth weight following delivery,
they concluded that impairment of the developing state was
due to confounding rather than antihypertensive exposure.
Beta-blocker summary: In summary, exposure to beta-
blockers in the setting of hypertension, was associated with
an increased risk of preterm birth, being small for gesta-
tional age, increased perinatal mortality and low birth
Fitton et al.
2130 www.jhypertension.com Volume 35  Number 11  November 2017
weight; however, there was limited evidence to suggest that
this increased risk was due to the medication rather than the
underlying hypertensive disease, with only six of 13 studies
reporting increased risk controlling for underlying hyper-
tension. There was also some evidence of an increased risk
of cardiovascular malformations; however, relevant studies
did not include an untreated comparison group [28,29].
Three RCTs [42,44,53], which included appropriate control
groups, reported no significant risk of other outcomes,
including hypotension, depressed respiratory rate, and
hypoglycemia. The ORs for perinatal mortality, preterm
birth, and congenital cardiovascular defects are reported
as Forest plots in Supplementary Figs. 2–4, http://links.
lww.com/HJH/A805.
Calcium channel blocker exposure
Three RCTS [34,62,63], one case–control study [35] and four
cohort studies [12,23,24,33] have reported the effects of in-
utero exposure to calcium channel blockers on the fetus
and child. Table 3 reports details on study type, outcomes,
and number of participants for studies assessing in-utero
exposure to calcium channel blocker medication. One
study was graded as excellent quality [33], five as mediocre
[12,34,35,62,63] and the remaining three studies as poor in
quality [23,24,36].
In the one study rated as excellent, Bateman et al. [33]
reported no increased odds of neonatal seizures associated
with calcium channel blocker exposure, compared with
those unexposed to any calcium channel blocker in
the third trimester of pregnancy (adjusted OR 1.0; 95% CI
0.7–1.3) in a cohort of 2529 636 women.
Gruppo [34], in an RCT of 283 women, rated as mediocre,
reported no increased risk of low birthweight, spontaneous
abortion, intrauterine death, or admission to NICU after
birth. Questionnaire follow-up at 18-month postdelivery of
190 of the 283 women [36], demonstrated no increased risk
of congenital malformations, or in occurrence of health
problems (impairments in gross/fine motor skills, hearing,
sight or language, or respiratory conditions) between off-
spring exposed in utero to nifedipine and offspring without
in-utero antihypertensive exposure.
Magee et al. [23] reported an increased rate of preterm
birth following in-utero calcium channel blocker exposure
(28 vs. 9%; P¼ 0.003) compared with normotensive
untreated women in a poor cohort study of 156 women.
The authors [23] reported no increased risk of low birth
weight (mean 3.0 kg vs. 3.4 g; P¼ 0.08), or congenital
malformations (3 vs. 0%; P¼ 0.27) among offspring with
in-utero exposure to calcium channel blockers.
Weber-Schoendorfer et al. [24], in a cohort study of 1105
women rated as poor, reported increased odds of preterm
birth (adjusted OR 4.6; 95% CI 2.9–7.3), low mean birth
weight (3.2 vs. 3.3 kg; P¼ 0.007), miscarriages (14 vs. 7.6%;
adjusted OR 2.2; 95% CI 1.4–3.5) associated with in-utero
exposure to calcium channel blockers compared with an
untreated normotensive group. The authors [24] reported
no significantly increased odds of stillbirths (adjusted OR
3.0; 95% CI 1.0–8.7), or birth defects (3.5 vs. 1.9%; P¼ 0.10)
with in-utero exposure to calcium channel blockers com-
pared with an untreated normotensive group.
Hall et al. [62] reported the results of a mediocre
RCT assessing the addition of nifedipine or prazosin to
existing antihypertensive medication in 145 women. The
use of prazosin was associated with a higher number of
intrauterine deaths compared with nifedipine (7 vs. 1;
P¼ 0.03).
In a mediocre case–control study of 54 016 women,
involving 22 865 cases taken from the Hungarian Congen-
ital Abnormality Registry and 38 151 controls without mal-
formations, Sorensen et al. [35] reported increased odds of
hypospadias (adjusted OR 3.5; 95% CI 1.4–8.6) following
in-utero calcium channel blocker exposure during the first
trimester, compared with the control group. Exposure to
calcium channel blockers between 4 and 9 months of
gestation was also associated with increased odds of car-
diovascular abnormalities (adjusted OR 1.4; 95% CI 1.2–
1.7), undescended testis (adjusted OR 1.5; 95% CI 1.1–1.9),
and multiple congenital abnormalities (adjusted OR 1.4;
95% CI 1.0–1.9) in cases compared with controls.
In an RCT of 49 hypertensive women rated as mediocre,
Fenakel et al. [63] reported no significant difference in birth
weight, gestational age, congenital malformations, and
perinatal death between the offspring of 24 hypertensive
women treated with nifedipine and 25 hypertensive
women treated with hydralazine.
In a mediocre cohort study of 87 407 pregnant women,
Davis et al. [12] reported an increased risk of congenital
abnormalities of the upper alimentary tract (RR 7.2; 95% CI
1.9–27.5) in offspring exposed to calcium channel blockers
during the first trimester in comparison with an untreated
normotensive reference group. Davis et al. [12] also
reported an increased risk of perinatal jaundice (RR 1.4;
95% CI 1.2–1.6), hematological disorders (RR 2.6; 95% CI
1.4–5.1) and convulsions in the new-born (RR 3.6; 95% CI
1.3–10.4) following in-utero exposure during the third
trimester of pregnancy.
Calcium channel blocker summary. In summary, the
results of the calcium channel blocker studies are mixed,
with evidence of increased perinatal mortality from two
RCTs, increased odds of preterm birth and perinatal
mortality from the cohort studies, and evidence of increased
malformations from the case–control study. None of the
reviewed studies assessed the effect of untreated hyperten-
sion on outcomes, thus limiting the interpretation of the
data and the relative importance of in-utero exposure rather
than underlying disease. The ORs for perinatal mortality,
preterm birth, and congenital cardiovascular defects are
reported as Forest plots in Supplementary Figs. 2–4, http://
links.lww.com/HJH/A805.
Angiotensin-converting enzyme inhibitor and
AT1 blocker exposure
One case–control study [28] and seven cohort studies
[22,29,56–60] have reported the effects of in-utero exposure
to ACEis and ARBs on the fetus and child. Table 4 reports
details on the study types, outcomes, and number of
participants for studies assessing in-utero exposure to ACEi
or ARB medication. Four studies were of poor quality
[22,56,58,59], two were of mediocre quality [28,60], and
two were excellent quality [29,57].
In-utero exposure to antihypertensive patients
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In a cohort study involving 465 754 offspring, rated as
excellent, Li et al. [57] reported increased odds of any birth
defect with exposure to ACEi therapy during the second or
third trimester compared with an untreated normotensive
group (adjusted OR 2.3; 95% CI 1.1–5.2). There were no
increased odds of congenital defects (adjusted OR 1.9; 95%
OR 0.8–4.2) associated with in-utero ACEi exposure in
comparison with an untreated hypertensive group. The
authors [57] reported no increased risk of congenital defects
in the first trimester following in-utero ACEi exposure
compared with both an untreated normotensive group
and an untreated hypertensive group. The authors did
report increased odds of any congenital defect among
the offspring of untreated hypertensive women, in com-
parison with those of untreated normotensive women (OR
1.25; 95% CI 1.2–1.3).
In a cohort study involving 1063 238 women, rated as
excellent, Lennestål et al. [29] reported no significantly
increased risk of congenital malformations (3.3%; RR 2.9;
95% CI 0.9–6.8) associated with the use of ACEis during
pregnancy compared with those who did not report any
antihypertensive use. There was, however, an increased
risk with exposure to any antihypertensive excluding ACEis
(OR 2.54; 95% CI 1.84–3.52) in comparison with no
antihypertensive use.
In contrast, in a cohort study rated as poor, comparing
ACEi and/or ARB (252 women) therapy vs. other antihy-
pertensive therapy (256 women) or nonteratogenic
exposure (495 women), Diav-Citrin et al. [22] reported an
increased incidence of preterm delivery (21.2 vs. 8.0%;
P< 0.001), low birth weight (median 3.0 vs. 3.3 kg;
P< 0.001), lower gestational age (median 38 vs. 40 weeks;
P< 0.001), and miscarriage (11.5 vs. 6.3%; P¼ 0.021)
associated with in-utero exposure to an ACEi or ARB, in
comparison with a nonteratogen-exposed group. Diav-Cit-
rin et al. [22] did not observe an increased rate of stillbirth
(1.2 vs. 0.8%; P¼ 0.838) or congenital malformations (4.2
vs. 3.8%; P¼ 0.954).
Tabacova et al. [59] reported a stillbirth rate of 11.0%, a
preterm delivery rate of 64.3%, and a congenital abnormal-
ity rate of 32.5%, following enalapril exposure in 108
pregnancies, in a poor cohort study; however, there was
no comparison group. The authors [59] also reported oli-
gohydramnios and specific adverse outcomes (limb
deformities, cranial ossification deficits, lung hypoplasia),
thought to be secondary to reduced amniotic fluid volume
rather than neonatal renal failure.
Moretti et al. [58] reported an increased incidence of
miscarriage (P< 0.001), lower birth weight (P< 0.001), and
lower gestation ages (P< 0.001) in those exposed to ACEi
or ARBs compared with those exposed to other antihyper-
tensive medications and untreated normotensive mothers,
in a cohort study of 388 women, rated as poor. The authors
[58] reported no increased risk of congenital malformations
following in-utero ACEi or ARB exposure in comparison
with other antihypertensive patients or the untreated
normotensive reference (1.8, 1.9, and 1.6%, respectively;
P¼ 0.99).
Caton et al. [28] reported increased odds of being pre-
natally exposed to antihypertensive ACEi/ARBs in cases
with Ebstein malformation (OR 26.4; 95% CI 2.3–306) in a
mediocre case–control study of 5021 cases and 4796 con-
trols. Karthikeyan et al. [56] reported a similar miscarriage
rate (11.8 vs. 10.0%), and developmental abnormality rate
(8.8 vs. 10.0%) between ACEis and ARBs, in a poor cohort
study of 94 women. In a mediocre cohort study involving
29 507 offspring, Cooper et al. [60] reported an increased
risk of malformations associated with exposure to ACEis in
the first trimester (7.1 vs. 2.6%; RR 2.7; 95% CI 1.7–4.3).
ACEi and ARB summary. In summary, ACEi and ARBs
were associated with an increased risk of preterm delivery
and miscarriage. The results relating to congenital abnor-
malities were conflicting with four studies reporting no
increased risk and five reporting increased risk. The results,
as a whole, are further confounded by the lack of inclusion
of an untreated hypertensive group. The ORs for congenital
cardiovascular defects are reported as a Forest plot in
Supplementary Fig. 4, http://links.lww.com/HJH/A805.
Methyldopa exposure
Two cohort studies [51,65] and three RCTs [49,50,52]
reported the results of in-utero exposure to methyldopa
and outcomes in the fetus and child. Table 5 reports details
on the study type, outcomes, and number of participants for
studies assessing in-utero exposure to methyldopa. One
study was of poor quality [65], three were of mediocre
quality [49,50,52], and one was scored as excellent [51] on
both the quality and bias tools.
In the only study rated as excellent, Orbach et al. [51]
reported an increased incidence of preterm birth (adjusted
OR 4.2; 95% CI 3.2–5.5), perinatal death (adjusted OR 2.1;
95% CI 1.1–4.0), low birth weight (adjusted OR 3.8; 95% CI
2.9–4.9), intrauterine growth restriction (adjusted OR 4.3;
95% CI 2.8–6.6), and low Apgar scores (7) at 1min
(adjusted OR 2.0; 1.4–2.7) and 5 min (adjusted OR 2.8;
95% CI 1.5–5.4), following exposure to methyldopa in
the third trimester in 99 514 women, in comparison with
an untreated normotensive reference group.
In a cohort study of 1223 women rated as poor, Xie et al.
[65] reported similar preterm birth rates (27.3 vs. 26%) in
those exposed to methyldopa during pregnancy, compared
with those who were exposed to labetalol. Cockburn et al.
[49] reported no differences in BP, or health issues between
babies exposed in-utero to methyldopa, and those unex-
posed in a mediocre RCT of 195 women. At 4 years of age,
boys in the unexposed group has larger head circumfer-
ences than those exposed to methyldopa between 16 and
20-week gestation (P< 0.05). However, there was no differ-
ence in IQ or behavior.
Fidler et al. [52] observed no difference in head circum-
ference, placental weight, or adjusted birth weight between
the methyldopa exposed group and an oxoprenolol or
nonexposed group in a mediocre RCT of 100 women. In
a RCT of 25 women, Weitz et al. [50] reported no significant
differences in birthweight, head circumference, ponderal
index, perinatal death, or 1 and 5min Apgar scores between
13 hypertensive mothers treated with methyldopa during
pregnancy and 12 hypertensive mothers given a placebo, in
a mediocre RCT.
Methyldopa summary. In summary, methyldopa
exposure was associated with an increased risk of preterm
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birth, perinatal mortality, and low birth weight. The RCTs
reported no difference among methyldopa exposed off-
spring in other outcomes such as BP, IQ, behavior and
placental weight. An increased risk of intrauterine growth
restriction and low Apgar scores was reported by one
cohort study. However, the study designs used did not
permit any conclusions to be drawn as to the relative
importance of in-utero methyldopa exposure vs. the under-
lying effects of hypertension on the offspring. The ORs for
perinatal mortality and preterm birth are reported as Forest
plots in Supplementary Figs. 2 and 3, http://links.lww.com/
HJH/A805.
Diuretic exposure
One linkage cohort study [25] involving 47 386 offspring
from Denmark and Scotland, reported the in-utero effects
of diuretics. The study identified increased odds of preterm
delivery associated with antenatal exposure to diuretics
among Danish offspring (OR 1.8; 95% CI 1.2–2.7) but
not Scottish offspring (OR 1.9; 95% CI 0.9–4.3). There
was also an increased risk of low birth weight associated
with diuretic use in the Danish offspring (OR 1.7; 95% CI
1.1–2.7) but not the Scottish offspring (OR 1.8; 95% CI 0.7–
5.1).
Studies assessing the long-term outcomes of
antihypertensive exposure
One RCT [49] and three cohort studies [11,13,61] have
investigated the effects of antihypertensive medication
exposure in utero on later childhood development. The
RCT [49] and two cohort studies [11,13] assessed labetalol
vs. methyldopa and a control group, whereas the other
cohort study [61] assessed the effect of clonidine. Table 6
reports details on study types, outcomes, and number of
participants for studies assessing long-term effects of in-
utero exposure to antihypertensive medication. Three stud-
ies were graded as mediocre [11,13,49] and one as poor
[61] quality.
Cockburn et al. [49], in a mediocre RCT, investigated
exposure to methyldopa in 195 offspring, followed up to 7
years of age. There were no differences in health outcomes,
such as sight and hearing, IQ, and behavioural develop-
ment between the methyldopa and untreated hypertensive
groups.
Chan et al. [11], investigated the effects of in-utero
exposure to labetalol or methyldopa in comparison with
no potential teratogen exposure in 99 offspring 3–7 years
postdelivery. The authors reported no significant differ-
ences in full-scale IQ, performance IQ or verbal IQ between
the labetalol and the control groups in the mediocre
cohort study.
In a mediocre cohort study of 202 patients, Pasker-De
Jong et al. [13] investigated the potential effects of methyl-
dopa or labetalol, compared with a hypertensive control
group treated with bed rest. Labetalol exposure was associ-
ated with nonsignificantly higher odds of attention deficit
hyperactive disorder compared with the methyldopa group
(OR 2.3; 95% CI 0.7–7.3), and significantly higher odds
compared with the bed rest group (OR 4.1; 95% CI 1.2–
13.9). Although sleeping disorders were more frequent
among the offspring of those treated with methyldopa
compared with labetalol (OR 3.2; 95% CI 0.6–16.7) and
bed rest (OR 4.5; 95% CI 0.9–23.2), neither result was
statistically significant.
In a poor cohort study of 44 patients, Huisjes et al. [61]
reported no significant difference in head circumference,
neurological findings, or school performance between off-
spring exposed to clonidine and the unexposed groups.
There was, however, an excess of hyperactivity and sleep
disturbances reported by the parents and teachers in
exposed offspring. Sleep disturbances were more severe
in those children exposed to clonidine 300 mg or more
in utero, suggesting a possible dose–response relationship.
DISCUSSION
The current study reviewed 47 published studies reporting
the effects of in-utero exposure to antihypertensive medi-
cation on the fetus and child. Thirty-two of these studies
were of poor or mediocre quality, with small study popu-
lations, and incomplete adjustment for confounding, and
lack of quality.
Although there is a widely held view that antihyperten-
sive patients, such as beta-blockers, may be associated with
a variety of detrimental fetal outcomes, such as low birth
weight or congenital malformations, these beliefs are not
based on robust data from appropriately designed and
powered studies to conclusively confirm any associations.
Furthermore, few studies have investigated the possible
long-term outcomes following in-utero exposure to anti-
hypertensive agents. The four studies which have done so
have had small study populations, lacked statistical power
and reported conflicting results. Although no IQ or devel-
opmental differences were reported for methyldopa and
labetalol in two studies [11,49], sleep disturbance following
clonidine [61] or methyldopa [13] exposure, and increased
incidence of attention deficit hyperactivity disorder with
labetalol [13] were reported in two of the four studies
reporting long-term outcomes.
The five studies graded as excellent [29,31,33,51,57]
suffered from confounding associated with the selection
and nature of the comparison groups and the way in which
medication exposure was reported.
One of the excellent studies assessing any antihyperten-
sive medications by Lennestål et al. [29] reported an
increased risk of cardiovascular defects following beta-
blocker exposure, or exposure to more than one antihy-
pertensive medication. This study, however relied on self-
reported drug exposure during the first trimester by women
during the first midwife visit. Analysis was based on women
reporting any antihypertensive use (excluding beta-block-
ers), irrespective of whether they had a diagnostic code for
chronic hypertension and women reporting beta-blocker
use only if they also had a diagnostic code for chronic
hypertension. Thus introducing recall bias and excluding
women who may have been treated with beta-blockers
but were not coded for chronic hypertension in their
medical records.
The results of their study seem to indicate a beta-blocker
driven association for congenital abnormalities; however,
the increased frequency of such abnormalities may have
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been due to the underlying chronic hypertension. The
authors fail to mention the severity of hypertension present
in patients, which would impact on treatments used and
outcomes of pregnancy. Furthermore, as the authors used
only one point of reference to establish drug exposure, it is
possible that as pregnancy progressed women may have
experienced altered exposure to different antihypertensive
patients or other potentially teratogenic agents, possibly
confounding the results further. Lastly, because BP was not
reported in the first midwife visit at wh‘ich medication use
was established it is not possible to determine whether
patients in the untreated comparison group were truly
normotensive. Therefore, the reported increase in the
prevalence of congenital abnormalities and birth outcomes
(preterm birth, placental abruption, delivery inductions)
reported in this study may be related to underlying,
or inadequately controlled, hypertension rather than
antihypertensive therapy.
The second excellent study to assess any antihyperten-
sive exposure during pregnancy by Nakhai-Pour et al. [31],
reported an increased risk of being small for gestational age
following exposure in the second or third trimester; how-
ever, there was no risk following exposure in the first
trimester, or any increased risk of having a congenital
anomaly following exposure to antihypertensive medi-
cation during any trimester in pregnancy. The authors
did not disclose what the indication for or duration of
the medication. Exposure therefore could be for a condition
other than hypertension, or could be a one-time exposure,
or for the last week of pregnancy, for example in the case of
tocolysis. There was also no consideration of the effects of
any underlying hypertension in the exposed group. The
unexposed group may also have been affected by under-
lying hypertension as diagnosis of normotensive patients
was not established.
The one study graded as excellent in quality assessing
ACEi exposure during pregnancy, reported an increased
risk of birth defects when compared with an untreated
normotensive group, but no difference when compared
with an untreated hypertensive control group [57]. How-
ever, the authors did not supply information on the type or
severity of hypertension in women included in the
untreated hypertensive comparison group. It is likely that
women in the untreated hypertensive control group may
have had less severe hypertension justifying no treat-
ment, thus potentially confounding the results. The fact
that the authors reported no differences in birth defects
between the ACEi-treated and untreated hypertensive
groups, and an increased risk for untreated hypertensive
women in comparison with untreated normotensive
women, suggests that hypertension alone, rather than
medication, could be the association of the detrimental
pregnancy outcomes.
The only study to assess calcium channel blocker
exposure during the last 30 days of pregnancy rated as
excellent, reported no increased risk of seizures compared
with an unexposed normotensive comparison group [33].
This study was limited by the single outcome reported. The
authors provided no information regarding the diagnosis,
reason for calcium channel blocker therapy, other drugs
taken, and no information regarding the unexposed cohort.
The fourth study deemed excellent was conducted by
Orbach et al. [51], who investigated the outcomes following
atenolol or methyldopa exposure during pregnancy. The
authors reported an increased risk of preterm birth, being
small for gestational age, low birth weight, and intrauterine
growth restriction; however, all but low birth weight was
also reported in the untreated hypertensive group. No
increased risk of congenital defects or deaths was reported
following exposure to atenolol or methyldopa. Those
classed as having been exposed had a prescription for either
atenolol or methyldopa in the first trimester. There was,
however, no further information regarding concomitant drug
exposure reported during the first trimester or the remainder
of the pregnancy. Theunexposed normotensive comparison
group had no prescriptions for antihypertensive medication
in the first and third trimester, and none had a diagnosis of
chronic hypertension. However, it is possible that women in
the untreated normotensive comparison group may have
developed gestational hypertension. The last comparison
group was untreated hypertensive women with a diagnosis
of chronic hypertension but no prescriptions for any anti-
hypertensive medication. The authors gave no information
regarding the severity of hypertension in this control group
possibly leading to selection bias as those treated may have
had more severe hypertension.
Twelve of the 47 studies included in this review were
RCTs; 11 of which were reported between 1982 and 2000.
The gold standard for study design is an RCT, however, the
need for randomization may conflict with the ethical treat-
ment of hypertensive pregnant women and so introduce
selection bias in the control groups.
Women included in these RCTs were often hospitalized
for severe preeclampsia as reported by Heida et al. [38],
which included a nontreated hypertensive group. The
study populations included in the RCTs were therefore
not representative of all hypertensive pregnant women
and the use of treated and untreated preeclampsia intro-
duces the possibility of further confounding. Furthermore,
the fact that no RCTs have been undertaken since 2006 may
again reflect the issues concerning the ethics of failure to
treat pregnant women.
The study population size in the RCTs reviewed in this
paper was between 25 and 300 patients. As the studies were
small scale, they may have lacked statistical power.
The majority of reviewed studies were case–control or
cohort studies in design, which inherently introduces the
issue of confounding from unknown or unmeasured con-
founders, underlying or poorly controlled hypertension,
and the issue of medication adherence. Studies using data
from poison centers or teratology centers [22,24] may
introduce selection bias, as women who contact these
services and then are later enrolled onto a study are unlikely
to be representative of the general population. In the six
case–control studies [22,26–28,30,35], exposure was only
reported by the women, and not validated by any other
means, for example, prescription records, which may have
introduced recall bias. Case–control studies also suffer from
survival bias, as cases are identified and information gath-
ered about exposure.
It is unclear whether the magnitude of the increased
risks, such as birth defects [29,57], reported by these studies
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are clinically significant; however, even if these results are
not deemed clinically significant to individuals, there may
still be an important impact on populations which have a
high prevalence of antihypertensive medication use. It is
generally stated that the background incidence of congen-
ital abnormalities in a healthy population is between 1 and
3%; however, this is likely to vary between populations.
From this point of view, large-scale linkage studies have the
advantage in permitting the calculation of a relatively
accurate population based estimate of the outcomes of
interest, compared with other types of methodology for
collecting data.
The results are further confounded by the lack of infor-
mation describing the types of hypertension treated in
women included in the exposed groups. It is likely that
the risk profiles and outcomes associated with chronic
hypertension, gestational hypertension, and preeclampsia
are different; therefore, a knowledge of the underlying
condition is important and should be considered and
reported. Only 16 of 47 studies reported in this review
provided such information, and the majority of these stud-
ies assessed beta-blocker exposure.
Although it is recognized that the results of cohort studies
should be reported as RR, ten of the cohort studies [13,24–
26,29,33,40,43,51,57,65] used logistic regression analysis
and reported results as OR values. Although the OR may
represent a close approximation to the RR when the out-
come of interest is rare (<10% of the general population/
unexposed group), OR values may exaggerate the risk
posed by the exposure studied and open the study
to misinterpretation.
Treatment of hypertension during pregnancy and assess-
ing the potential risks to the offspring is further complicated
by the underlying disease. Untreated hypertension results
in preterm birth, low birth weight and increased mortality. It
would therefore be reasonable to suggest that poorly
controlled hypertension may carry the same risks as
untreated hypertension. Case–control and cohort studies
reviewed in this paper have failed to determine whether
hypertension was appropriately treated and controlled, and
failed to assess adherence. Several studies reviewed
[37,38,45,57] used an untreated hypertensive group to
identify whether there was an increased risk in these cases;
however, results were mixed with some studies reporting
an increased risk compared with untreated hypertension
[37,45], whereas others reported no difference [38,57].
Limitations to this review include exclusion of confer-
ence abstracts, unpublished studies, studies reported in any
language other than English or German, which may have
resulted in possible publication bias. However, when
the literature search was performed, only two articles
were excluded due to language. A further limitation was
the wide date-range over which the included studies
were published, the majority before 2000. As a result
attempted contact with authors was either impractical
or unsuccessful.
In conclusion, adverse child outcomes such as preterm
birth, perinatal mortality, low birth weight, risk of congen-
ital abnormalities, or other detrimental outcomes, following
in-utero antihypertensive exposure have been reported in
the literature. However, most published studies have had
methodological weaknesses and/or lacked statistical power
thus preventing any firm conclusions being drawn.
Further research in this area is required to ensure that
health professionals have sufficient data to treat hyperten-
sion during pregnancy to firmly demonstrate a lack of
detrimental outcomes.
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Reviewers’ Summary Evaluations
Reviewer 1
Strengths: A better understanding of the impact of in utero
exposure to antihypertensive medication is important, parti-
cularly with the increasing prevalence of hypertension and
similar risk factors in women of childbearing age. This manu-
script nicely brings together the current state of the literature.
In doing so, the need for more high quality, well designed
studies on potential benefits and adverse outcomes of anti-
hypertensive treatments in pregnancy becomes apparent.
Weaknesses: The field provides insufficient information
to discriminate between potentially complex adverse
effects of the different types of hypertensive conditions
(preeclampsia, pregnancy-induced or preexisting hyper-
tension) and the antihypertensive medications used to
treat them.
Reviewer 2
This article’s strengths are its use of consensus-determined
systematic review methods, careful consideration of study
quality, and inclusion of relevant details from many differ-
ent study types. This article’s weaknesses are the incon-
clusive nature of the results, which was dependent on the
studies available for review.
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